EY declines reappointment as Lifecore auditor; cites material weaknesses in internal controls

LIFECORE BIOMEDICAL, INC. DE

Ernst & Young notified Lifecore on March 20, 2024 it will not stand for reappointment as auditor for FY ending May 26, 2024.
EY issued adverse opinions on internal controls for FY2023 and FY2022 due to material weaknesses.
EY's FY2022 audit report included a going-concern explanatory paragraph.
No accounting disagreements; company is actively seeking a new independent registered public accounting firm.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.